Genmab (GMAB)
(Delayed Data from NSDQ)
$26.43 USD
-0.64 (-2.36%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.44 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Brokerage Reports
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 101 - 116 ( 116 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Pipeline Focus in 2020; 2019 Financials; Reiterate Buy; Raising PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Another DARZALEX Regimen Regulatory Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
CASSIOPEIA Regimen Receives European Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Front-Line Regimen Wins European Thumbs up; Teprotumumab Clears FDA Panel Vote; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Continues to Deliver Clinical Benefit
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Sales Cross $2.5B Threshold, Triggering $100M Milestone Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab Vedotin Cervical Cancer Data Incrementally Positive in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
As Anticipated, DARZALEX Front-Line MAIA Regimen Wins Approval in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous ASH Abstracts; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
CHMP Issues Positive Opinion on DARZALEX Front-Line MAIA Regimen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 3Q19 Sales Reported; Reiterate Buy and Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
FDA Approves CASSIOPEIA Regimen for 1L Transplant-Eligible Multiple Myeloma Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ARZERRA Matches OCREVUS; Positive GRIFFIN and CANDOR Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Management Highlights Pipeline at Genmab Breakfast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Arzerra Set to Take on Roche''s Ocrevus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Converting to US Listing; Reiterate Buy and $24 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R